Abstract Search

ea0056p20 | Adrenal cortex (to include Cushing's) | ECE2018

Prevalance of primary aldosteronism in hypertensive patients: epidemiological data from a tertiary centre

Voulgaris Nikolaos , Papanastasiou Labrini , Vlachou Sofia , Kyriazi Evangelia , Tyfoxylou Ernestini , Monastirioti Nikoletta , Kapsali Chara , Charalampidou Liana , Aglaia Zachaki , Kalantzi Athanasia , Gravvanis Christos , Markou Athina , Giagourta Eirini , Kounadi Theodora , Kassi Eva , Kaltsas Gregory , Piaditis George

Introduction: Primary aldosteronism (PA) is the most common cause of endocrine hypertension. Its prevalence varies from 5-15%, which depends mainly on the cut-offs of the diagnostic tests.Aim: To estimate the prevalence of PA in patients with different stages of hypertension based on a dynamic overnight diagnostic test.Methods: One hundred ninety nine hypertensive patients were divided in 3 groups according to the stage of hyperten...

0 shares

ea0056p21 | Adrenal cortex (to include Cushing's) | ECE2018

Renin: a possible novel marker for the efficacy of pharmacological treatment of primary aldosteronism

Voulgaris Nikolaos , Vlachou Sofia , Kyriazi Evangelia , Papaoikonomou Eleni , Tyfoxylou Ernestini , Monastirioti Nikoletta , Kapsali Chara , Zachaki Aglaia , Charalampidou Liana , Kounadi Theodora , Markou Athina , Papanastasiou Labrini , Giagourta Eirini , Kassi Eva , Kaltsas Gregory , Piaditis George

Introduction: Primary aldosteronism (PA) treatment is either pharmacological with aldosterone receptor antagonists (MRAs) or surgical with the resection of the responsible adenoma. The efficacy of MRAs treatment is based on the normalization of blood pressure (BP) in relation to potassium levels. However, it remains unclear whether the stimulation of renin levels during treatment could serve as an additional marker of adequate MR blockade.Aim: To investi...

0 shares

Endocrine Abstracts

Prevalance of primary aldosteronism in hypertensive patients: epidemiological data from a tertiary centre

Renin: a possible novel marker for the efficacy of pharmacological treatment of primary aldosteronism

BiosciAbstracts